Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design

DM Beckwith, M Cudic - Seminars in immunology, 2020 - Elsevier
The transformation from normal to malignant phenotype in human cancers is associated with
aberrant cell-surface glycosylation. It has frequently been reported that MUC1, the heavily …

Glycans in drug discovery

P Valverde, A Ardá, NC Reichardt… - …, 2019 - pubs.rsc.org
Glycans are key players in many biological processes. They are essential for protein folding
and stability and act as recognition elements in cell–cell and cell–matrix interactions. Thus …

An inherent difference between serine and threonine phosphorylation: phosphothreonine strongly prefers a highly ordered, compact, cyclic conformation

AK Pandey, HK Ganguly, SK Sinha… - ACS Chemical …, 2023 - ACS Publications
Phosphorylation and dephosphorylation of proteins by kinases and phosphatases are
central to cellular responses and function. The structural effects of serine and threonine …

Aberrant glycosylation as immune therapeutic targets for solid tumors

Y Matsumoto, T Ju - Cancers, 2023 - mdpi.com
Simple Summary Glycosylation is one of the most pivotal post-translational modifications on
all types of biomolecules for the formation of glycoproteins, glycolipids, and glycoRNAs in a …

Perspectives on anti-glycan antibodies gleaned from development of a community resource database

E Sterner, N Flanagan, JC Gildersleeve - ACS chemical biology, 2016 - ACS Publications
Antibodies are used extensively for a wide range of basic research and clinical applications.
While an abundant and diverse collection of antibodies to protein antigens have been …

Molecular recognition of GalNAc in mucin-type O-glycosylation

I Sanz-Martinez, S Pereira, P Merino… - Accounts of Chemical …, 2023 - ACS Publications
Conspectus N-Acetylgalactosamine (GalNAc)-type O-glycosylation is an essential
posttranslational modification (PTM) that plays fundamental roles in biology. Malfunction of …

Potential of anti-MUC1 antibodies as a targeted therapy for gastrointestinal cancers

M Bose, P Mukherjee - Vaccines, 2020 - mdpi.com
Gastrointestinal cancers (GI) account for 26% of cancer incidences globally and 35% of all
cancer-related deaths. The main challenge is to target cancer specific antigens. Mucins are …

Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides

N Martínez-Sáez, JM Peregrina… - Chemical Society Reviews, 2017 - pubs.rsc.org
Cancer is currently one of the world's most serious public health problems. Significant efforts
are being made to develop new strategies that can eradicate tumours selectively without …

Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation

M Wang, J Wang, R Wang, S Jiao, S Wang… - Communications …, 2019 - nature.com
Abstract Programmed cell death 1 (PD-1) is inhibitory receptor and immune checkpoint
protein. Blocking the interaction of PD-1 and its ligands PD-L1/L2 is able to active T-cell …

Mucins and pathogenic mucin-like molecules are immunomodulators during infection and targets for diagnostics and vaccines

S Pinzón Martín, PH Seeberger, D Varón Silva - Frontiers in chemistry, 2019 - frontiersin.org
Mucins and mucin-like molecules are highly O-glycosylated proteins present on the cell
surface of mammals and other organisms. These glycoproteins are highly diverse in the …